查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1690113

药用管瓶和安瓿瓶：市场占有率分析、产业趋势和成长预测（2025-2030 年）

Pharmaceutical Glass Vials And Ampoules - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2025 - 2030)
出版日期: | 出版商: Mordor Intelligence | 英文 154 Pages | 商品交期: 2-3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

预计 2025 年药用管瓶和安瓿瓶市场规模为 158.5 亿美元，到 2030 年将达到 221.7 亿美元，预测期内（2025-2030 年）的复合年增长率为 6.94%。

药用玻璃瓶和安瓿瓶-市场-IMG1

玻璃长期以来一直是医药包装行业安全包装的黄金标准，是保持各种化学成分的完美材料。此外，玻璃管瓶和安瓿瓶透明度高，易于检查和监控其内容物。

主要亮点

  • 製药业的成长推动着市场的成长。人口稠密的国家对药用管瓶和安瓿瓶的需求较大。这些国家正在增加药品产量，进一步增加了需求。此外，印度和中国等新兴经济体医疗保健支出的增加也推动了市场成长。
  • 新兴市场因其良好的人口结构、低廉的人事费用和丰富的资源而被认为是一个不断增长和繁荣的国家。金砖国家（巴西、俄罗斯、印度、中国和南非）是领先的新兴经济体。
  • 对子经济体进行分类有几种不同的方法。 MIST 国家包括墨西哥、印尼、韩国和土耳其。还有一种解释是把这些国家分为灵猫国（哥伦比亚、印尼、越南、埃及、土耳其和南非）和孟加拉、埃及、印尼、伊朗、韩国、墨西哥、奈及利亚、巴基斯坦、菲律宾、土耳其和越南。
  • 玻璃的关键性能优势，例如其化学耐久性和保持多种化学成分的能力，正在促使包装供应商选择它作为医药材料。
  • 此外，玻璃管瓶和安瓿瓶透明度高，可轻鬆检视和监控内容物。由于玻璃对大多数药物具有耐化学性，并且相对渗透性空气和水分，因此这提供了进一步的保护。
  • 传统上，药品包装所使用的材料是铝和玻璃。随着时间的推移，这些材料由于原材料价格和其他因素而变得昂贵，并且不再为包装大众消费产品提供经济可行的解决方案。这时，塑胶就成为一种选择。

药用管瓶和安瓿瓶的市场趋势

疫苗将占据很大市场占有率

  • 疫苗需求的增加以及慢性病盛行率的上升推动了医药包装产业的整体成长。因此，管瓶和安瓿瓶市场预计将大幅成长。
  • 疫苗包装解决方案需求的激增得益于消费者购买的大量疫苗以及世界卫生组织和联合国儿童基金会等主流组织组织的大规模疫苗接种活动。这导致医院、诊断中心、研究项目和其他医疗保健单位等终端使用领域对玻璃安瓿瓶和管瓶的需求大幅增加。
  • 此外，由于持续控制感染疾病的努力、大流行病的爆发以及对疫苗接种重要性的认识不断提高等各种因素，全球对疫苗的需求正在稳步增长。
  • 在整个製造过程中，技术转移和伙伴关係将显着影响供应的灵活性和扩充性，尤其是在 COVID-19 疫苗的开发过程中。许多製造商从其他製造商接收散装疫苗，然后将其装入管瓶、安瓿瓶和包装中进行分发。
  • 药品包装（尤其是疫苗包装）的严格监管要求通常倾向于使用玻璃，因为玻璃具有化学惰性且能够承受灭菌过程。这种合规性推动了对药品包装中管瓶和安瓿瓶的需求。确保为全球疫苗分发提供足够的药用管瓶供应对于全球应对的成功至关重要。世界各国政府和製药公司正在下达数亿份订单，促使初级包装玻璃製造商提高生产能力。
  • 这些努力在许多国家都取得了成功，各国政府都采购并管理了疫苗。例如，截至 2023 年 11 月，印度政府已接种超过 22 亿剂 COVID-19 疫苗。根据CNN和OWID报道，截至2023年3月20日，全球已接种约130亿剂新冠疫苗，其中美国接种了约6.72亿剂。

亚太地区：预计大幅成长

  • 随着中国建立了製药业的标准框架，中国药用玻璃安瓿瓶和管瓶市场预计将扩大。在国内，人们越来越重视药品包装材料在药品储存过程中的稳定性以及包装在使用时的安全性。由于玻璃包装具有耐用性、非反应性、透明度、环境相容性和多功能性，製药公司越来越多地采用玻璃包装。此外，由于医疗保健系统和研发方面的投资增加以及医药支出的增加，管瓶的需求量很大。
  • 日本製药业是继美国之后世界上成长最快的产业之一。这是因为日本持续致力于开发学名药及疫苗，以及政府对希望在日本投资的国际公司采取放鬆管制的措施。 2023年5月，全球最大的公司之一日本尼普洛株式会社（Nipro Corporation Japan）宣布将在塞斯韦特（Sesvete）工厂投资超过1亿披索（2648万美元），为製药业建造一个新的安瓿瓶和管瓶工厂（药品），即尼普洛製药（克罗埃西亚）。 Nipro Corporation Japan 从 Blue Sea Capital Fund 手中收购了前 Piramida 工厂（Sesvete）（最近被评为年度最成功的收购）。
  • 随着印度製药业的成长，印度对玻璃包装的需求预计将会增加。随着行业参与者专注于抓住市场成长，他们正在建立玻璃管设施，以帮助製药商应对日益复杂的产能和品质挑战，同时满足印度市场对基本药物的需求。
  • 例如，2023年7月，美国科技公司康宁与法国药用玻璃製造商SGD Pharma的合资企业将在印度特伦甘纳邦建立一家药用玻璃管工厂，以扩大印度的药品生产规模。新厂将康宁专有的玻璃涂层技术平台 Velocity 管瓶与 SGD Pharma 的管瓶转换专业知识相结合，以提高管瓶和填充生产线的生产效率，并加速全球注射疗法的交付。
  • 新工厂的奠基仪式将于 2023 年 6 月举行，该公司预计将向该工厂投资约 50 亿印度卢比（6,030 万美元），并创造约 150 个就业机会。 Velocity管瓶的生产预计将于 2024 年在 SGD Pharma 的 Vemula 工厂开始，药用导管的生产预计将于 2025 年开始。
  • 注射剂的需求正在增长，因为它们避免了口服营养素所带来的许多问题。随着医疗保健需求的增加，对管瓶和安瓿瓶包装的药品、疫苗和其他医疗产品的需求也在增加，这给这些药品的生产带来了压力。这导致製药公司转向契约製造。例如，2023年5月，创新软体、生命科学和深度科技公司开发商Bridgewest Group推出了一家专注于无菌注射药物的新的合约开发和受託製造厂商（CDMO）。 CMDO 将设在西澳大利亚，并在 NovaCina 旗下运作。

药用管瓶和安瓿瓶产业概况

药用管瓶和安瓿瓶市场分散，主要参与者包括 Schott AG、Gerresheimer AG、Stevanato Group、Nipro Corporation 和 Kapoor Glass India Pvt。有限公司。市场上的公司正在采取联盟和收购等策略来加强其产品供应并获得永续的竞争优势。

  • 2023 年 10 月 - Gerresheimer 推出 COP（环状烯烃聚合物）管瓶，这是适用于填充和储存敏感生物製药的解决方案。 COP管瓶非常适合在低温和低温环境中与 mRNA 活性成分一起使用。 Gerresheimer 提供各种品质的 RTF管瓶，采用结合了玻璃和塑胶最佳性能的高品质聚合物。
  • 2023 年 2 月 - NOVA Ompi 签署预售协议，以约 1.6 亿欧元（1691 万美元）的价格收购位于义大利拉廷的一块棕地地，该地靠近斯蒂瓦那托集团的其他工厂。维修后，棕地工厂将生产 EZ-fill 注射器、管瓶和其他产品。

其他福利

  • Excel 格式的市场预测 (ME) 表
  • 3个月的分析师支持

目录

第一章 引言

  • 研究假设和市场定义
  • 研究范围

第二章调查方法

第三章执行摘要

第四章 市场洞察

  • 市场概览
  • 产业吸引力－波特五力分析
    • 供应商的议价能力
    • 买家的议价能力
    • 新进入者的威胁
    • 替代品的威胁
    • 竞争对手之间的竞争强度
  • COVID-19 产业影响评估
  • 产业价值链分析

第五章市场动态

  • 市场驱动因素
    • 新兴国家製药业的成长
    • 提高可回收玻璃的商业价值
  • 市场限制
    • 替代原料的重要性日益增加

第六章市场区隔

  • 按应用
    • 疫苗
    • 其他（胰岛素、生物製药等）
  • 按地区
    • 北美洲
      • 美国
      • 加拿大
    • 欧洲
      • 德国
      • 英国
      • 法国
      • 义大利
      • 西班牙
    • 亚洲
      • 中国
      • 日本
      • 印度
      • 韩国
      • 澳洲和纽西兰
    • 拉丁美洲
    • 中东和非洲

第七章竞争格局

  • 公司简介
    • Schott AG
    • Gerresheimer AG
    • Stevanato Group SPA
    • NIPRO Corporation
    • Kapoor Glass India Pvt. Ltd
    • SGD SA（SGD Pharma）
    • AAPL Solutions Pvt. Ltd
    • CORNING INCORPORATED
    • BOROSIL
    • Stoelzle Oberglas GmbH
    • Accu-Glass LLC
    • Adit Containers Private Limited
    • Agrado SA
    • Birgimefar Group
    • J. Penner Corporation
    • BORMIOLI PHARMA SPA
    • SISECAM

第八章投资分析

第九章：市场的未来

简介目录
Product Code: 69988

The Pharmaceutical Glass Vials And Ampoules Market size is estimated at USD 15.85 billion in 2025, and is expected to reach USD 22.17 billion by 2030, at a CAGR of 6.94% during the forecast period (2025-2030).

Pharmaceutical Glass Vials And Ampoules - Market - IMG1

Glass has long been the go-to material for safe packaging in the pharmaceutical packaging industry and is best suited to sustaining various chemical compositions. Also, glass vials and ampoules provide enhanced transparency, which allows easy inspection and monitoring of their contents.

Key Highlights

  • The growing pharmaceutical industry aids the market's growth. The demand for pharmaceutical glass vials and ampoules arises in densely populated countries. The increasing pharmaceutical production in these countries is further increasing demand. In addition, growing healthcare spending in developing countries like India and China is another driver of the market's growth.
  • Emerging markets are described as growing and prosperous nations owing to their favorable demographic conditions, low labor costs, and abundant resources. The BRICS nations (Brazil, Russia, India, China, and South Africa) are the top developing economies.
  • There are a few different approaches to classifying lower-tier economies. MIST countries include Mexico, Indonesia, South Korea, and Turkey. Another interpretation separates the two groups into CIVETS (Colombia, Indonesia, Vietnam, Egypt, Turkey, and South Africa) and Bangladesh, Egypt, Indonesia, Iran, Korea, Mexico, Nigeria, Pakistan, the Philippines, Turkey, and Vietnam.
  • The significant characteristic benefits of glass, such as chemical durability and suitability to sustain various chemical compositions, are some factors driving packaging vendors to choose glass as a pharmaceutical material.
  • Additionally, glass vials and ampoules offer improved transparency, making viewing and monitoring the contents easier. This provides additional protection because glass is chemically resistant to most pharmaceuticals and comparatively impermeable to air and moisture.
  • Traditionally, the preferred materials across pharmaceutical packaging have been aluminum and glass. Over time, these materials became expensive due to raw material prices and other factors and could not provide economically viable solutions for packaging products across mass consumption. That marked the advent of plastics as an option.

Pharmaceutical Glass Vials and Ampoules Market Trends

Vaccines to Hold Significant Market Share

  • The increasing demand for vaccines, coupled with the rising prevalence of chronic diseases, contributes to the overall growth of the pharmaceutical packaging industry. The market for glass vials and ampoules is expected to witness a substantial increase as a result.
  • The surge in demand for vaccine packaging solutions is aided by the high number of vaccines acquired by consumers and the major vaccination drives organized by mainstream organizations like WHO and UNICEF. This has led to a significant increase in demand for glass ampoules and vials in end-use sectors such as hospitals, diagnostic centers, research programs, and other healthcare units.
  • Furthermore, the global demand for vaccines has been steadily increasing due to various factors, including ongoing efforts to combat infectious diseases, emerging pandemics, and a growing awareness of the importance of vaccination.
  • The flexibility and scalability of supply are greatly impacted by technology transfers and partnerships throughout the manufacturing process, particularly with the development of COVID-19 vaccines. Many manufacturers rely on receiving bulk vaccines from another manufacturer that they then fill into vials, ampoules, and packages for distribution.
  • Stringent regulatory requirements for pharmaceutical packaging, especially for vaccines, often favor using glass due to its chemical inertness and the ability to withstand sterilization processes. This compliance drives the demand for glass vials and ampoules in pharmaceutical packaging. Ensuring an adequate supply of pharmaceutical glass vials for the distribution of the vaccine worldwide is crucial for the success of a global response. Governments and pharmaceutical companies worldwide are placing hundreds of millions of orders and urging primary packaging glass manufacturers to increase their production capacity.
  • These initiatives proved successful in many countries, acquiring and administrating vaccines by their respective governments. For example, as of November 2023, the Indian government had administered more than 2.2 billion COVID-19 vaccinations. According to CNN and OWID, as of March 20, 2023, about 13 billion COVID-19 vaccine doses had been administered globally, with the United States accounting for almost 672 million.

Asia Pacific Expected to Witness Major Growth

  • The Chinese pharmaceutical glass ampoules and vials market is expected to expand as China has established a standard framework for the pharmaceutical industry. The country is increasingly focusing on the stability of pharmaceutical packaging materials during drug storage and the safety of the packaging when used. Pharmaceutical companies increasingly use glass packaging because of its durability, non-reactivity, transparency, eco-friendliness, and versatility. Additionally, glass vials are in high demand due to increasing investment and R&D in healthcare systems and rising drug spending.
  • Japan's pharmaceutical industry is one of the fastest growing in the world, second only to the United States. This is due to the country's continued focus on developing generic and patented drugs and vaccines and the government's deregulatory measures for international companies wishing to invest in the country. In May 2023, Nipro Corporation Japan, one of the world's largest companies, presented its investment of over PGK 100 million (USD 26.48 million) at the Sesvete plant, where it is constructing a new ampoules and vial factory (Pharmaceuticals) Nippro Pharma Packaging (Hrvatska) for the pharmaceutical industry. Nippro Corporation Japan purchased the old Piramida factory (Sesvete) from the Blue Sea Capital fund (which was recently named the year's most successful acquisition).
  • The demand for glass packaging in India is expected to increase as the Indian pharmaceutical industry grows. Players in the industry are focusing on capitalizing on market growth, so they are opening glass tubing facilities to help the companies support drug manufacturers in addressing progressively complex capacity and quality challenges while fulfilling the need for essential medicines in the Indian market.
  • For instance, in July 2023, a joint venture between United States technology company Corning and French pharmaceutical glassmaker SGD Pharma will build a pharmaceutical glass tubing facility in the Indian state of Telangana to scale up pharmaceutical manufacturing in India. The new facility will bring together Corning's proprietary glass coating technology platform, Velocity Vial, and SGD Pharma's vial converting expertise to enhance vial and fill-line productivity and the delivery speed for injectable treatments worldwide.
  • The groundbreaking ceremony for the new facility was held in June 2023, and the company expects to invest approximately INR 5 billion (USD 60.3 million) in the facility, which is expected to create about 150 jobs. The manufacturing of Velocity Vials is expected to start at SGD Pharma's Vemula facility in 2024, with the production of pharmaceutical tubing expected to begin in 2025.
  • The demand for injectables is increasing as they can bypass many issues plaguing orally administered nutrients. As healthcare needs increase, the demand for pharmaceuticals, vaccines, and other medical products packaged in vials and ampoules will also increase, creating pressure on the production of such medicines. This leads to pharmaceutical companies switching to contract manufacturers. For instance, in May 2023, Bridgewest Group, a company developing innovative software, life sciences, and deep tech companies, launched a new contract development and manufacturing organization (CDMO) focusing on sterile injectable drug products. The CMDO is located in Western Australia and will operate under NovaCina.

Pharmaceutical Glass Vials and Ampoules Industry Overview

The pharmaceutical glass vials and ampoules market is fragmented, with the presence of major players like Schott AG, Gerresheimer AG, Stevanato Group, Nipro Corporation, and Kapoor Glass India Pvt. Ltd. Players in the market are adopting strategies such as partnerships and acquisitions to enhance their product offerings and gain sustainable competitive advantage.

  • October 2023 - Gerresheimer has launched vials containing COP (Cyclic Olefin Polymer), a suitable solution for filling and storing susceptible biological products. COP vials are ideal for using mRNA-active ingredients in cold and cryogenic environments. Gerresheimer is broadening its range of RTF glass vials, which are available in various qualities, with a high-quality polymer that combines the best properties of both glass and plastic.
  • February 2023 - NOVA Ompi entered into a pre-sale agreement to purchase a brownfield site in Latin (Italy), close to other facilities of the Stevanato group, for an approximate price of EUR 16,0 million (USD 16.91 million). After renovation, the brownfield site is expected to produce EZ-filled syringes, vials, and other products.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET INSIGHTS

  • 4.1 Market Overview
  • 4.2 Industry Attractiveness - Porter's Five Forces Analysis
    • 4.2.1 Bargaining Power of Suppliers
    • 4.2.2 Bargaining Power of Buyers
    • 4.2.3 Threat of New Entrants
    • 4.2.4 Threat of Substitutes
    • 4.2.5 Intensity of Competitive Rivalry
  • 4.3 Assessment of the Impact of COVID-19 on the Industry
  • 4.4 Industry Value Chain Analysis

5 MARKET DYNAMICS

  • 5.1 Market Drivers
    • 5.1.1 Growth of the Pharmaceutical Industry in Emerging Economies
    • 5.1.2 Commodity Value of Glass Increased with Recyclability
  • 5.2 Market Restraints
    • 5.2.1 Increased Relevance of Alternate Sources

6 MARKET SEGMENTATION

  • 6.1 By Application
    • 6.1.1 Vaccines
    • 6.1.2 Others (Insulin, Biopharma, Others)
  • 6.2 By Geography
    • 6.2.1 North America
      • 6.2.1.1 United States
      • 6.2.1.2 Canada
    • 6.2.2 Europe
      • 6.2.2.1 Germany
      • 6.2.2.2 United Kingdom
      • 6.2.2.3 France
      • 6.2.2.4 Italy
      • 6.2.2.5 Spain
    • 6.2.3 Asia
      • 6.2.3.1 China
      • 6.2.3.2 Japan
      • 6.2.3.3 India
      • 6.2.3.4 South Korea
      • 6.2.3.5 Australia and New Zealand
    • 6.2.4 Latin America
    • 6.2.5 Middle East and Africa

7 COMPETITIVE LANDSCAPE

  • 7.1 Company Profiles
    • 7.1.1 Schott AG
    • 7.1.2 Gerresheimer AG
    • 7.1.3 Stevanato Group SPA
    • 7.1.4 NIPRO Corporation
    • 7.1.5 Kapoor Glass India Pvt. Ltd
    • 7.1.6 SGD SA (SGD Pharma)
    • 7.1.7 AAPL Solutions Pvt. Ltd
    • 7.1.8 CORNING INCORPORATED
    • 7.1.9 BOROSIL
    • 7.1.10 Stoelzle Oberglas GmbH
    • 7.1.11 Accu-Glass LLC
    • 7.1.12 Adit Containers Private Limited
    • 7.1.13 Agrado SA
    • 7.1.14 Birgimefar Group
    • 7.1.15 J. Penner Corporation
    • 7.1.16 BORMIOLI PHARMA SPA
    • 7.1.17 SISECAM

8 INVESTMENT ANALYSIS

9 FUTURE OF THE MARKET